⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Venous Thromboembolism in Primary Pancreatic Tumour Resection

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Venous Thromboembolism in Primary Pancreatic Tumour Resection

Official Title: Venous Thromboembolism in Patients Undergoing Primary Pancreatic Tumour Resection; a Prospective Observational Study

Study ID: NCT05964621

Interventions

Study Description

Brief Summary: This study will evaluate the development of venous thromboembolism (VTE) and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection.

Detailed Description: Cancer associated thrombosis (CAT) is the second cause of death, in oncologic patients after tumour progression itself. Patients suffering from malignancies are at increased risk for both venous (4-20%) and arterial (2-5%) thrombotic events. Moreover, cancer is one of the most important acquired risk factors for the development of venous thromboembolism (VTE). Pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy, with a reported incidence of VTE (8-18%), followed by renal and ovarian cancer (VTE 5.6%). Although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state. Aims * To evaluate the predictive value of preoperatively or early postoperatively obtained NLR, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day * To evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkers/parameters, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for VTE up to the 30rd postoperative day * To evaluate the incidence of VTE in patients with primary pancreatic cancer undergoing pancreatic cancer resection * To assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection * To evaluate any possible determinant or predictive factor for VTE among the coagulation parameters or patients' baseline characteristics

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University Hospital of Larissa, Larissa, Thessaly, Greece

Contact Details

Name: Eleni M Arnaoutoglou, Professor

Affiliation: Dpt of Anaesthesiology

Role: STUDY_CHAIR

Name: Dimitrios Zacharoulis, Professor

Affiliation: Dpt of Surgery

Role: PRINCIPAL_INVESTIGATOR

Name: Paraskevi Kotsi, Asst Professor

Affiliation: Dpt of Transfusion Medicine

Role: PRINCIPAL_INVESTIGATOR

Name: Dimitrios Symeonidis, Asst Professor

Affiliation: Dpt of Surgery

Role: PRINCIPAL_INVESTIGATOR

Name: Maria P Ntalouka, M.D., Ph.D, M.Sc.

Affiliation: Dpt of Anaesthesiology

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: